Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Fluorometholone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 known ✓ | P04150 | 6/20 | 0.93 |
| ▸ | HIF1A | Q16665 | 10/20 | 0.93 |
| ▸ | CYP3A4 | P08684 | 10/20 | 0.93 |
| ▸ | LMNA | P02545 | 5/20 | 0.93 |
| ▸ | PGR | P06401 | 5/20 | 0.93 |
| ▸ | NR1I2 | O75469 | 3/20 | 0.93 |
| ▸ | GAA | P10253 | 1/20 | 0.93 |
| ▸ | HTT | P42858 | 1/20 | 0.93 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.93 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | AR | P10275 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fluorometholone SCHEMBL13069233 | 0.96 | HIF1A (1.00) | HIF1ACYP3A4NR3C1LMNAPGR | |
| Fluorometholone SCHEMBL5187733 | 0.96 | HIF1A (1.00) | HIF1ACYP3A4NR3C1LMNAPGR | |
| Fluorometholone SCHEMBL19327160 | 0.96 | HIF1A (1.00) | HIF1ACYP3A4NR3C1LMNAPGR | |
| Fluorometholone SCHEMBL9415488 | 0.96 | HIF1A (1.00) | HIF1ACYP3A4NR3C1LMNAPGR | |
| Fluorometholone SCHEMBL13026152 | 0.96 | HIF1A (1.00) | HIF1ACYP3A4NR3C1LMNAPGR | |
| Fluorometholone SCHEMBL23975162 | 0.96 | HIF1A (1.00) | HIF1ACYP3A4NR3C1LMNAPGR | |
| Fluorometholone SCHEMBL5187729 | 0.96 | HIF1A (1.00) | HIF1ACYP3A4NR3C1LMNAPGR | |
| Fluorometholone SCHEMBL14769393 | 0.96 | HIF1A (1.00) | HIF1ACYP3A4NR3C1LMNAPGR | |
| Fluorometholone SCHEMBL13069734 | 0.96 | HIF1A (1.00) | HIF1ACYP3A4NR3C1LMNAPGR | |
| Fluorometholone SCHEMBL5051 | 0.96 | HIF1A (1.00) | HIF1ACYP3A4NR3C1LMNAPGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 122 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12274681-B2 | Compositions and methods for reducing skin fat | PURDUE RESEARCH FOUNDATION (US) | 2025-04-15 | — | — | US | claimed |
| US-20230270701-A1 | COMPOSITIONS AND METHODS FOR REDUCING SKIN FAT | PURDUE RESEARCH FOUNDATION | 2023-08-31 | — | — | US | claimed |
| US-9855295-B2 | Methods of using ophthalmic compositions comprising povidone-iodine | CLARUS CLS HOLDINGS, LLC (US) | 2018-01-02 | — | — | US | claimed |
| CN-105944105-A | POVIDONE IODINE, A NOVEL ALTERNATIVE PRESERVATIVE FOR OPHTHALMIC COMPOSITIONS | 前瞻生物治疗公司 | 2016-09-21 | — | — | CN | claimed |
| CN-104906580-A | Non-irritating ophthalmic povidone-iodine compositions | FORESIGHT BIOTHERAPEUTICS INC | 2015-09-16 | — | — | CN | claimed |
| CN-103889218-A | Stabilized povidone-iodine compositions | FORESIGHT BIOTHERAPEUTICS INC | 2014-06-25 | — | — | CN | claimed |
| CN-103463635-A | Ophthalmic compositions comprising povidone-iodine | CLS PHARMACEUTICALS INC | 2013-12-25 | — | — | CN | claimed |
| CN-102811610-A | Non-irritating Ophthalmic Povidone-iodine Compositions | FORESIGHT BIOTHERAPEUTICS INC | 2012-12-05 | — | — | CN | claimed |
| CN-102118973-A | Povidone-iodine as antiseptic substitute for ophthalmic composition | FORESIGHT BIOTHERAPEUTICS INC | 2011-07-06 | — | — | CN | claimed |
| WO-2009145842-A9 | THERAPEUTIC DEVICE FOR PAIN MANAGEMENT AND VISION | FORSIGHT LABS, LLC (US) | 2010-11-18 | — | — | WO | claimed |
| CN-101400355-A | Ophthalmic compositions comprising povidone-iodine | CLS PHARMACEUTICALS INC (US) | 2009-04-01 | — | — | CN | claimed |
| EP-1740168-A2 | ANTIPROSTAGLANDINS FOR THE TREATMENT OF OCULAR PATHOLOGIES | Advanced Ocular Systems Limited (AU) | 2007-01-10 | — | — | EP | claimed |
| EP-1720555-A1 | TETRACYCLINE DERIVATIVES FOR THE TREATMENT OF OCULAR PATHOLOGIES | Advanced Ocular Systems Limited (AU) | 2006-11-15 | — | — | EP | claimed |
| EP-1718314-A1 | HEPARIN FOR THE TREATMENT OF OCULAR PATHOLOGIES | Advanced Ocular Systems Limited (AU) | 2006-11-08 | — | — | EP | claimed |
| US-20060122152-A1 | Heparin for the treatment of ocular pathologies | MINU, LLC | 2006-06-08 | — | — | US | claimed |
| US-20050261243-A1 | Antiprostaglandins for the treatment of ocular pathologies | MINU, LLC | 2005-11-24 | — | — | US | claimed |
| US-20050256081-A1 | Tetracycline derivatives for the treatment of ocular pathologies | MINU, LLC | 2005-11-17 | — | — | US | claimed |
| WO-2005102303-A2 | ANTIPROSTAGLANDINS FOR THE TREATMENT OF OCULAR PATHOLOGIES | ADVANCED OCULAR SYSTEMS LIMITED (AU) | 2005-11-03 | — | — | WO | claimed |
| WO-2005082376-A1 | TETRACYCLINE DERIVATIVES FOR THE TREATMENT OF OCULAR PATHOLOGIES | ADVANCED OCULAR SYSTEMS LIMITED (AU) | 2005-09-09 | — | — | WO | claimed |
| WO-2005082380-A1 | HEPARIN FOR THE TREATMENT OF OCULAR PATHOLOGIES | ADVANCED OCULAR SYSTEMS LIMITED (AU) | 2005-09-09 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12274681-B2 | Compositions and methods for reducing skin fat | ACAT1, ACAT2, ACACA | NR3C1 1078/4885HIF1A 3174/4885CYP3A4 1885/4885 |
| US-20230270701-A1 | COMPOSITIONS AND METHODS FOR REDUCING SKIN FAT | ACAT1, ACAT2, ACACA | NR3C1 1078/4885HIF1A 3174/4885CYP3A4 1885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.